AMBOSS provides a medical knowledge platform that combines high-quality clinical content with AI-supported technology to aid medical education and point-of-care decision-making. The product is positioned as a digital co-pilot for clinicians, delivering precise, actionable recommendations on diagnostics and treatment based on current guidelines. AMBOSS reports over 1 million professional users across more than 180 countries and a team of over 500 employees, and the platform is widely used by medical students and residents in the US and clinicians in Germany. The company emphasizes long-standing, responsible use of AI and rigorous validation of outcomes. Recent strategic moves include the 2024 acquisitions of Novaheal (nursing) and NEJM Knowledge+ (US board prep). Looking ahead, AMBOSS plans to expand into additional international markets and broaden its offering to nurses and other health care professionals, while continuing selective acquisitions and further investment in technology.

Total raised

$282M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2025